申请人:LAPKO INC. dba AFECTA PHARMACEUTICALS
公开号:US20220142961A1
公开(公告)日:2022-05-12
Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.